{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T17:56:00Z","timestamp":1781718960227,"version":"3.54.5"},"reference-count":26,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Br J Ophthalmol"],"accepted":{"date-parts":[[2026,5,28]]},"abstract":"<jats:sec>\n                    <jats:title>Background\/aims<\/jats:title>\n                    <jats:p>Evaluation of durability outcomes after switching to aflibercept 8\u2009mg for macular oedema in retinal vein occlusion (RVO).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We evaluated eyes with branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO), switching from other anti-vascular endothelial growth factor treatments to off-label aflibercept 8\u2009mg under an observe-and-plan regimen. Eyes receiving ongoing treatment with \u226510 prior injections were eligible. Treatment discontinuation during the 12-month follow-up period resulted in exclusion. All data were obtained through the review of medical records.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The overall cohort of eyes with RVO (n=156) achieved a mean interval gain of +1.6 weeks at 12 months (p&lt;0.0001). The proportion of eyes treated at \u22646-week intervals decreased from 37.8% at switch to 17.9% at 12-month follow-up (p&lt;0.0001) while the proportion on intervals \u22659 weeks increased from 37.8% at switch to 60.3% (p&lt;0.0001). The CRVO subgroup (n=65) achieved a mean increase in interval length at 12 months of +2.0 weeks (p&lt;0.0001) and +3.0 weeks in the case of a dry macula at switch (p&lt;0.0001). The BRVO subgroup (n=91) achieved an overall increase in interval length of +1.3 weeks (p&lt;0.0001) and +2.3 weeks for eyes with a dry macula at switch (p&lt;0.0001). The central retinal thickness decreased from 262.8\u00b179.4\u2009\u00b5m to 244.6\u00b159.5\u2009\u00b5m (p=0.0012) while best recorded visual acuity remained unchanged at 68.2 Early Treatment Diabetic Retinopathy Study letters at 12 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Switching to aflibercept 8\u2009mg substantially reduced the proportion of eyes on short intervals without compromising visual outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bjo-2025-329273","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T17:20:19Z","timestamp":1781716819000},"page":"bjo-2025-329273","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Insights on Switching Aflibercept Dosage for Enhanced Outcomes in Retinal Vein Occlusion (RISE-RVO): visual, anatomical and durability outcomes"],"prefix":"10.1136","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-2130-6649","authenticated-orcid":false,"given":"Chi Tuyet","family":"Nguyen","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Aalborg University Hospital, Aalborg, Denmark"},{"name":"Department of Clinical Medicine, Aalborg University, Aalborg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9814-7236","authenticated-orcid":false,"given":"Rasmus Klock B\u00f8gh","family":"Lassen","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Aalborg University Hospital, Aalborg, Denmark"},{"name":"Department of Clinical Medicine, Aalborg University, Aalborg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3376-9364","authenticated-orcid":false,"given":"Mads Odgaard","family":"M\u00e6ng","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Aalborg University Hospital, Aalborg, Denmark"},{"name":"Department of Clinical Medicine, Aalborg University, Aalborg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celine","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Aalborg University Hospital, Aalborg, Denmark"},{"name":"Department of Clinical Medicine, Aalborg University, Aalborg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousif","family":"Subhi","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Rigshospitalet, Copenhagen, Capital Region of Denmark, Denmark"},{"name":"Department of Ophthalmology, University of Southern Denmark, Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Vorum","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Aalborg University Hospital, Aalborg, Denmark"},{"name":"Department of Clinical Medicine, Aalborg University, Aalborg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles C","family":"Wykoff","sequence":"additional","affiliation":[{"name":"Retina Consultants of Texas, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1433-5528","authenticated-orcid":false,"given":"Marie","family":"\u00d8rskov","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Aalborg University Hospital, Aalborg, Denmark"},{"name":"Department of Clinical Medicine, Aalborg University, Aalborg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lasse J\u00f8rgensen","family":"Cehofski","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Aalborg University Hospital, Aalborg, Denmark"},{"name":"Department of Clinical Medicine, Aalborg University, Aalborg, Denmark"},{"name":"Retina Consultants of Texas, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"2026061710201139000_bjo-2025-329273v1.1","doi-asserted-by":"crossref","DOI":"10.7189\/jogh.09.010427","article-title":"Global epidemiology of retinal vein occlusion: a systematic review and meta-analysis of prevalence, incidence, and risk factors","volume":"9","author":"Song","year":"2019","journal-title":"J Glob Health"},{"key":"2026061710201139000_bjo-2025-329273v1.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2020.100921"},{"key":"2026061710201139000_bjo-2025-329273v1.3","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.61.13.6"},{"key":"2026061710201139000_bjo-2025-329273v1.4","doi-asserted-by":"crossref","first-page":"110462","DOI":"10.1016\/j.exer.2025.110462","article-title":"Integration of proteomics and artificial intelligence-driven OCT biomarker analysis in central retinal vein occlusion","volume":"258","author":"Ferro Desideri","year":"2025","journal-title":"Exp Eye Res"},{"key":"2026061710201139000_bjo-2025-329273v1.5","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.64.13.23"},{"key":"2026061710201139000_bjo-2025-329273v1.6","doi-asserted-by":"publisher","DOI":"10.1159\/000502041"},{"key":"2026061710201139000_bjo-2025-329273v1.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.08.038"},{"key":"2026061710201139000_bjo-2025-329273v1.8","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ajo.2019.03.029","article-title":"Loss of Peak Vision in Retinal Vein Occlusion Patients Treated for Macular Edema","volume":"205","author":"Iftikhar","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"2026061710201139000_bjo-2025-329273v1.9","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/aos.15721","article-title":"Prognostic modelling of number of patients with retinal vein occlusion in anti\u2010VEGF therapy","volume":"102","author":"Subhi","year":"2024","journal-title":"Acta Ophthalmol (Copenh)"},{"key":"2026061710201139000_bjo-2025-329273v1.10","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1080\/09286586.2020.1792937","article-title":"Real-World Visual and Neovascularisation Outcomes from anti-VEGF in Central Retinal Vein Occlusion","volume":"28","author":"Hogg","year":"2021","journal-title":"Ophthalmic Epidemiol"},{"key":"2026061710201139000_bjo-2025-329273v1.11","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1177\/1120672120904669","article-title":"Ranibizumab and aflibercept intravitreal injection for treatment na\u00efve and refractory macular oedema in branch retinal vein occlusion","volume":"31","author":"Hogg","year":"2021","journal-title":"Eur J Ophthalmol"},{"key":"2026061710201139000_bjo-2025-329273v1.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.09.035"},{"key":"2026061710201139000_bjo-2025-329273v1.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.08.012"},{"key":"2026061710201139000_bjo-2025-329273v1.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2012.09.026"},{"key":"2026061710201139000_bjo-2025-329273v1.15","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S0140-6736(24)00063-1","article-title":"Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial","volume":"403","author":"Lanzetta","year":"2024","journal-title":"The Lancet"},{"key":"2026061710201139000_bjo-2025-329273v1.16","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/S0140-6736(23)02577-1","article-title":"Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2\/3 trial","volume":"403","author":"Brown","year":"2024","journal-title":"The Lancet"},{"key":"2026061710201139000_bjo-2025-329273v1.17","unstructured":"Aflibercept 8 mg in treatment-na\u00efve macular edema secondary to retinal vein occlusion: primary endpoint results from the QUASAR study."},{"key":"2026061710201139000_bjo-2025-329273v1.18","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/aos.16709","article-title":"Injection burden and treatment intervals of aflibercept in observe-and-plan regimen for neovascular age-related macular degeneration","volume":"102","author":"Subhi","year":"2024","journal-title":"Acta Ophthalmol"},{"key":"2026061710201139000_bjo-2025-329273v1.19","unstructured":"I regeneron pharmaceuticals, EYLEA HD\u00ae (aflibercept) injection 8 mg phase 3 trial meets primary endpoint showing improved vision with extended dosing intervals in patients with macular edema following retinal vein occlusion. 2024. Available: https:\/\/newsroom.regeneron.com\/news-releases\/news-release-details\/eylea-hdr-aflibercept-injection-8-mg-phase-3-trial-meets-primary"},{"key":"2026061710201139000_bjo-2025-329273v1.20","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15051416","article-title":"Pharmacokinetic and Pharmacodynamic Rationale for Extending VEGF Inhibition Increasing Intravitreal Aflibercept Dose","volume":"15","author":"Veritti","year":"2023","journal-title":"Pharmaceutics"},{"key":"2026061710201139000_bjo-2025-329273v1.21","doi-asserted-by":"crossref","first-page":"3218","DOI":"10.1038\/s41433-024-03312-w","article-title":"Sustained disease control with aflibercept 8 mg: a new benchmark in the management of retinal neovascular diseases","volume":"38","author":"Korobelnik","year":"2024","journal-title":"Eye (Lond)"},{"key":"2026061710201139000_bjo-2025-329273v1.22","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27113360","article-title":"Proteome Analysis of Aflibercept Intervention in Experimental Central Retinal Vein Occlusion","volume":"27","author":"Cehofski","year":"2022","journal-title":"Molecules"},{"key":"2026061710201139000_bjo-2025-329273v1.23","article-title":"Aflibercept Intervention in Experimental Branch Retinal Vein Occlusion Results in Upregulation of DnaJ Homolog Subfamily C Member 17","volume":"2021","author":"Cehofski","year":"2021","journal-title":"J Ophthalmol"},{"key":"2026061710201139000_bjo-2025-329273v1.24","doi-asserted-by":"crossref","DOI":"10.1186\/s12886-026-04695-y","article-title":"Short-term real-world outcomes of switching to faricimab in anti-VEGF-refractory retinal vein occlusion: a prospective study","volume":"26","author":"Kilani","year":"2026","journal-title":"BMC Ophthalmol"},{"key":"2026061710201139000_bjo-2025-329273v1.25","doi-asserted-by":"crossref","DOI":"10.3390\/jcm14072454","article-title":"Switching to Faricimab in Therapy-Resistant Macular Edema Due to Retinal Vein Occlusion: Initial Real-World Efficacy Outcomes","volume":"14","author":"Hafner","year":"2025","journal-title":"J Clin Med"},{"key":"2026061710201139000_bjo-2025-329273v1.26","doi-asserted-by":"crossref","first-page":"100179","DOI":"10.1016\/j.ajoint.2025.100179","article-title":"Inflammation and increased intraocular pressure associated with intravitreal aflibercept 8 mg: A systematic review and meta-analysis","volume":"2","author":"Rebsdorf","year":"2025","journal-title":"AJO International"}],"container-title":["British Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bjo-2025-329273","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T17:20:23Z","timestamp":1781716823000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjo.bmj.com\/lookup\/doi\/10.1136\/bjo-2025-329273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":26,"alternative-id":["10.1136\/bjo-2025-329273"],"URL":"https:\/\/doi.org\/10.1136\/bjo-2025-329273","relation":{},"ISSN":["0007-1161","1468-2079"],"issn-type":[{"value":"0007-1161","type":"print"},{"value":"1468-2079","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]}}}